Effect of new antimicrobial agents on the ecological balance of human microflora

Anaerobe

Volumn 18, Issue 2, 2012, Pages 249-253

  Rashid, Mamun Ur ^a   Weintraub, Andrej ^a   Nord, Carl Erik ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Ecological impact; Human microflora; New antimicrobial agents

Indexed keywords

ANTIINFECTIVE AGENT; CEFTAROLINE; CEFTOBIPROLE; DALBAVANCIN; FIDAXOMICIN; TELAVANCIN; TIGECYCLINE; VANCOMYCIN;

ABDOMINAL INFECTION; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL COLONIZATION; BACTERIAL OVERGROWTH; BACTERIAL PNEUMONIA; BACTERIAL STRAIN; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM DIFFICILE INFECTION; COMMUNITY ACQUIRED PNEUMONIA; CONTINUOUS INFUSION; DRUG SAFETY; DRUG TOLERABILITY; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HOSPITAL ACQUIRED PNEUMONIA; HUMAN; INTESTINE FLORA; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MICROFLORA; MICROHABITAT; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; OROPHARYNX; PNEUMONIA; PRIORITY JOURNAL; SINGLE DRUG DOSE; SKIN INFECTION; STREPTOCOCCUS PNEUMONIAE; STREPTOCOCCUS PYOGENES; VANCOMYCIN RESISTANT ENTEROCOCCUS;

ANTI-INFECTIVE AGENTS; BIOTA; HUMANS; METAGENOME;

EID: 84859845173     PISSN: 10759964     EISSN: 10958274     Source Type: Journal    
DOI: 10.1016/j.anaerobe.2011.11.005     Document Type: Article

References (70)

1. Sullivan å., Edlund C., Nord C.E. Effect of antimicrobial agents on the ecological balance of human microflora. Lancet Infect Dis 2001, 1:101-114.
2. Sullivan å., Edlund C., Nord C.E. Interaction between antimicrobial agents and the oropharyngeal and intestinal microflora. Antimicrobial agents 2005, 1357-1370. ASM Press, Washington, DC. A. Bryskier (Ed.).
3. Nord C.E., Edlund C. Impact of antimicrobial agents on human intestinal microflora. J Chemother 1990, 2:218-237.
4. Davies J., Davies D. Origins and evolution of antibiotic resistance. Microbiol Mol Biol Rev 2010, 74:417-433.
5. van der Waaij D., Nord C.E. Development and persistence of multi-resistance to antibiotics in bacteria; an analysis and a new approach to this urgent problem. Int J Antimicrob Agents 2000, 16:191-197.
6. Edlund C., Nord C.E. Ecological impact of antimicrobial agents on human intestinal microflora. Alpe Adria Microbiol J 1993, 3:137-164.
7. Rao G.G. Risk factors for the spread of antibiotic-resistant bacteria. Drugs 1998, 55:323-330.
8. Shah D., Dang M.D., Hasbun R., Koo H.L., Jiang Z.D., DuPont H.L., et al. Clostridium difficile infection: update on emerging antibiotic treatment options and antibiotic resistance. Expert Rev Anti Infect Ther 2010, 8:555-564.
9. Rybak M.J., LaPlante K.L. Community-associated methicillin-resistant Staphylococcus aureus: a review. Pharmacotherapy 2005, 25:74-85.
10. Wadl M., Heckenbach K., Noll I., Ziesing S., Pfister W., Beer J., et al. Increasing occurrence of multidrug-resistance in Acinetobacter baumannii isolates from four German University Hospitals, 2002-2006. Infection 2010, 38:47-51.
11. Milloy M.J., Wood E. Transmitted antiretroviral-resistant HIV: a coming anarchy?. Lancet Infect Dis 2011, 11:336-337.
12. Miethke T. Increasing therapeutic challenges through multi-resistant bacteria in the hospital. Zentralbl Chir 2011, [Epub 2011/03/02].
13. Lynch J.P., Zhanel G.G. Streptococcus pneumoniae: does antimicrobial resistance matter?. Semin Respir Crit Care Med 2009, 30:210-238.
14. Johnson R., Streicher E.M., Louw G.E., Warren R.M., van Helden P.D., Victor T.C. Drug resistance in Mycobacterium tuberculosis. Curr Issues Mol Biol 2006, 8:97-111.
15. Guinovart C., Navia M.M., Tanner M., Alonso P.L. Malaria: burden of disease. Curr Mol Med 2006, 6:137-140.
16. Giessel B.E., Koenig C.J., Blake R.L. Management of bacterial endocarditis. Am Fam Physician 2000, 61:1725-1732. 39.
17. Calfee D.P. Clostridium difficile: a reemerging pathogen. Geriatrics 2008, 63:10-21.
18. McDonald L.C., Killgore G.E., Thompson A., Owens R.C., Kazakova S.V., Sambol S.P., et al. An epidemic, toxin gene-variant strain of Clostridium difficile. N Engl J Med 2005, 353:2433-2441.
19. Jones R.N. Resistance patterns among nosocomial pathogens: trends over the past few years. Chest 2001, 119:397S-404S.
20. Klevens R.M., Morrison M.A., Nadle J., Petit S., Gershman K., Ray S., et al. Invasive methicillin-resistant Staphylococcus aureus infections in the United States. JAMA 2007, 298:1763-1771.
21. Morel C.M., Mossialos E. Stoking the antibiotic pipeline. BMJ 2010, 340:c2115.
22. Higgins P.G., Dammhayn C., Hackel M., Seifert H. Global spread of carbapenem-resistant Acinetobacter baumannii. J Antimicrob Chemother 2010, 65:233-238.
23. Henrich T.J., Krakower D., Bitton A., Yokoe D.S. Clinical risk factors for severe Clostridium difficile-associated disease. Emerg Infect Dis 2009, 15:415-422.
24. Falagas M.E., Rafailidis P.I., Matthaiou D.K., Virtzili S., Nikita D., Michalopoulos A. Pandrug-resistant Klebsiella pneumoniae, Pseudomonas aeruginosa and Acinetobacter baumannii infections: characteristics and outcome in a series of 28 patients. Int J Antimicrob Agents 2008, 32:450-454.
25. Azap O.K., Arslan H., Serefhanoglu K., Colakoglu S., Erdogan H., Timurkaynak F., et al. Risk factors for extended-spectrum beta-lactamase positivity in uropathogenic Escherichia coli isolated from community-acquired urinary tract infections. Clin Microbiol Infect 2010, 16:147-151.
26. Choffnes E.R., Relman D.A., Mack A. Antibiotic resistance: implications for global health and novel intervention strategies: workshop summary 2010, National Academies Press, Washington, DC.
27. Richards T. Alliance pledges new cheap TB drug by 2010. BMJ 2000, 321:981.
28. Spellberg B., Guidos R., Gilbert D., Bradley J., Boucher H.W., Scheld W.M., et al. The epidemic of antibiotic-resistant infections: a call to action for the medical community from the Infectious Diseases Society of America. Clin Infect Dis 2008, 46:155-164.
29. Woerther P.L., Angebault C., Lescat M., Ruppe E., Skurnik D., Mniai A.E., et al. Emergence and dissemination of extended-spectrum beta-lactamase-producing Escherichia coli in the community: lessons from the study of a remote and controlled population. J Infect Dis 2010, 202:515-523.
30. Tomasz A. Multiple-antibiotic-resistant pathogenic bacteria. A report on the Rockefeller University Workshop. N Engl J Med 1994, 330:1247-1251.
31. Barbour A., Schmidt S., Rand K.H., Derendorf H. Ceftobiprole: a novel cephalosporin with activity against Gram-positive and Gram-negative pathogens, including methicillin-resistant Staphylococcus aureus (MRSA). Int J Antimicrob Agents 2009, 34:1-7.
32. Schirmer P.L., Deresinski S.C. Ceftobiprole: a new cephalosporin for the treatment of skin and skin structure infections. Expert Rev Anti Infect Ther 2009, 7:777-791.
33. Bäckström T., Panagiotidis G., Beck O., Asker-Hagelberg C., Rashid M.U., Weintraub A., et al. Effect of ceftobiprole on the normal human intestinal microflora. Int J Antimicrob Agents 2010, 36:537-541.
34. Ge Y., Biek D., Talbot G.H., Sahm D.F. In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States. Antimicrob Agents Chemother 2008, 52:3398-3407.
35. Zhanel G.G., Sniezek G., Schweizer F., Zelenitsky S., Lagace-Wiens P.R., Rubinstein E., et al. Ceftaroline: a novel broad-spectrum cephalosporin with activity against meticillin-resistant Staphylococcus aureus. Drugs 2009, 69:809-831.
36. Talbot G.H., Thye D., Das A., Ge Y. Phase 2 study of ceftaroline versus standard therapy in treatment of complicated skin and skin structure infections. Antimicrob Agents Chemother 2007, 51:3612-3616.
37. Panagiotidis G., Bäckström T., Asker-Hagelberg C., Jandourek A., Weintraub A., Nord C.E. Effect of ceftaroline on normal human intestinal microflora. Antimicrob Agents Chemother 2010, 54:1811-1814.
38. Higgins D.L., Chang R., Debabov D.V., Leung J., Wu T., Krause K.M., et al. Telavancin, a multifunctional lipoglycopeptide, disrupts both cell wall synthesis and cell membrane integrity in methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 2005, 49:1127-1134.
39. Lunde C.S., Hartouni S.R., Janc J.W., Mammen M., Humphrey P.P., Benton B.M. Telavancin disrupts the functional integrity of the bacterial membrane through targeted interaction with the cell wall precursor lipid II. Antimicrob Agents Chemother 2009, 53:3375-3383.
40. Rubinstein E., Lalani T., Corey G.R., Kanafani Z.A., Nannini E.C., Rocha M.G., et al. Telavancin versus vancomycin for hospital-acquired pneumonia due to gram-positive pathogens. Clin Infect Dis 2011, 52:31-40.
41. Saravolatz L.D., Stein G.E., Johnson L.B. Telavancin: a novel lipoglycopeptide. Clin Infect Dis 2009, 49:1908-1914.
42. Stryjewski M.E., Graham D.R., Wilson S.E., O'Riordan W., Young D., Lentnek A., et al. Telavancin versus vancomycin for the treatment of complicated skin and skin-structure infections caused by gram-positive organisms. Clin Infect Dis 2008, 46:1683-1693.
43. Finegold S.M., Bolanos M., Sumannen P.H., Molitoris D.R. In vitro activities of telavancin and six comparator agents against anaerobic bacterial isolates. Antimicrob Agents Chemother 2009, 53:3996-4001.
44. Rashid M.U., Weintraub A., Nord C.E. Effect of telavancin on the human intestinal microflora. Int J Antimicrob Agents 2011, 38:474-479.
45. Goldstein E.J., Citron D.M., Merriam C.V., Warren Y., Tyrrell K., Fernandez H.T. In vitro activities of dalbavancin and nine comparator agents against anaerobic gram-positive species and corynebacteria. Antimicrob Agents Chemother 2003, 47:1968-1971.
46. Streit J.M., Fritsche T.R., Sader H.S., Jones R.N. Worldwide assessment of dalbavancin activity and spectrum against over 6000 clinical isolates. Diagn Microbiol Infect Dis 2004, 48:137-143.
47. Seltzer E., Dorr M.B., Goldstein B.P., Perry M., Dowell J.A., Henkel T. Once-weekly dalbavancin versus standard-of-care antimicrobial regimens for treatment of skin and soft-tissue infections. Clin Infect Dis 2003, 37:1298-1303.
48. Raad I., Darouiche R., Vazquez J., Lentnek A., Hachem R., Hanna H., et al. Efficacy and safety of weekly dalbavancin therapy for catheter-related bloodstream infection caused by gram-positive pathogens. Clin Infect Dis 2005, 40:374-380.
49. Nord C.E., Rasmanis G., Wahlund E. Effect of dalbavancin on the normal intestinal microflora. J Antimicrob Chemother 2006, 58:627-631.
50. Boucher H.W., Wennersten C.B., Eliopoulos G.M. In vitro activities of the glycylcycline GAR-936 against gram-positive bacteria. Antimicrob Agents Chemother 2000, 44:2225-2229.
51. Gales A.C., Jones R.N. Antimicrobial activity and spectrum of the new glycylcycline, GAR-936 tested against 1,203 recent clinical bacterial isolates. Diagn Microbiol Infect Dis 2000, 36:19-36.
52. Jacobus N.V., McDermott L.A., Ruthazer R., Snydman D.R. In vitro activities of tigecycline against the Bacteroides fragilis group. Antimicrob Agents Chemother 2004, 48:1034-1036.
53. Petersen P.J., Jacobus N.V., Weiss W.J., Sum P.E., Testa R.T. In vitro and in vivo antibacterial activities of a novel glycylcycline, the 9-t-butylglycylamido derivative of minocycline (GAR-936). Antimicrob Agents Chemother 1999, 43:738-744.
54. Edlund C., Nord C.E. In-vitro susceptibility of anaerobic bacteria to GAR-936, a new glycylcycline. Clin Microbiol Infect 2000, 6:159-163.
55. Babinchak T., Ellis-Grosse E., Dartois N., Rose G.M., Loh E. The efficacy and safety of tigecycline for the treatment of complicated intra-abdominal infections: analysis of pooled clinical trial data. Clin Infect Dis 2005, 41(Suppl. 5):S354-S367.
56. Ellis-Grosse E.J., Babinchak T., Dartois N., Rose G., Loh E. The efficacy and safety of tigecycline in the treatment of skin and skin-structure infections: results of 2 double-blind phase 3 comparison studies with vancomycin-aztreonam. Clin Infect Dis 2005, 41(Suppl. 5):S341-S353.
57. Nord C.E., Sillerstrom E., Wahlund E. Effect of tigecycline on normal oropharyngeal and intestinal microflora. Antimicrob Agents Chemother 2006, 50:3375-3380.
58. Muto C.A., Pokrywka M., Shutt K., Mendelsohn A.B., Nouri K., Posey K., et al. A large outbreak of Clostridium difficile-associated disease with an unexpected proportion of deaths and colectomies at a teaching hospital following increased fluoroquinolone use. Infect Control Hosp Epidemiol 2005, 26:273-280.
59. Zilberberg M.D., Tillotson G.S., McDonald C. Clostridium difficile infections among hospitalized children, United States, 1997-2006. Emerg Infect Dis 2010, 16:604-609.
60. Gerding D.N. Metronidazole for Clostridium difficile-associated disease: is it okay for Mom?. Clin Infect Dis 2005, 40:1598-1600.
61. Shin J.W., Yong D., Kim M.S., Chang K.H., Lee K., Kim J.M., et al. Sudden increase of vancomycin-resistant enterococcal infections in a Korean tertiary care hospital: possible consequences of increased use of oral vancomycin. J Infect Chemother 2003, 9:62-67. discussion 104-5.
62. Crook D, Peto T, Miller M, Louie T, Cornely O, Shue YK, et al. Efficacy and safety of fidaxomicin (FDX) vs. vancomycin in Clostridium difficile infection (CDI) in 2 randomized controlled trials with 1105 patients [abstract]. 48th Annual Conference of the Infectious Disease Society of America. Vancouver; Canada:; 2010.
63. Ackermann G., Loffler B., Adler D., Rodloff A.C. In vitro activity of OPT-80 against Clostridium difficile. Antimicrob Agents Chemother 2004, 48:2280-2282.
64. Finegold S.M., Molitoris D., Vaisanen M.L., Song Y., Liu C., Bolanos M. In vitro activities of OPT-80 and comparator drugs against intestinal bacteria. Antimicrob Agents Chemother 2004, 48:4898-4902.
65. Hecht D.W., Galang M.A., Sambol S.P., Osmolski J.R., Johnson S., Gerding D.N. In vitro activities of 15 antimicrobial agents against 110 toxigenic Clostridium difficile clinical isolates collected from 1983 to 2004. Antimicrob Agents Chemother 2007, 51:2716-2719.
66. Karlowsky J.A., Laing N.M., Zhanel G.G. In vitro activity of OPT-80 tested against clinical isolates of toxin-producing Clostridium difficile. Antimicrob Agents Chemother 2008, 52:4163-4165.
67. Shue Y.K., Sears P.S., Shangle S., Walsh R.B., Lee C., Gorbach S.L., et al. Safety, tolerance, and pharmacokinetic studies of OPT-80 in healthy volunteers following single and multiple oral doses. Antimicrob Agents Chemother 2008, 52:1391-1395.
68. Louie T.J., Emery J., Krulicki W., Byrne B., Mah M. OPT-80 eliminates Clostridium difficile and is sparing of bacteroides species during treatment of C. difficile infection. Antimicrob Agents Chemother 2009, 53:261-263.
69. Louie T., Miller M., Donskey C., Mullane K., Goldstein E.J. Clinical outcomes, safety, and pharmacokinetics of OPT-80 in a phase 2 trial with patients with Clostridium difficile infection. Antimicrob Agents Chemother 2009, 53:223-228.
70. Tannock G.W., Munro K., Taylor C., Lawley B., Young W., Byrne B., et al. A new macrocyclic antibiotic, fidaxomicin (OPT-80), causes less alteration to the bowel microbiota of Clostridium difficile-infected patients than does vancomycin. Microbiology 2010, 156:3354-3359.